Windlas Biotech Limited (WINDLAS)
Investor Presentation
Investor Presentation - Q1FY27
- Revenue grew 18% YoY to Rs 248 Cr, highest quarterly revenue
- Adjusted EBITDA up 26% YoY to Rs 34 Cr; Adjusted PAT up 37% YoY to Rs 25 Cr
- Generic Formulations CDMO revenue rose 29% YoY to Rs 207 Cr
- Exports revenue surged 79% YoY to Rs 11 Cr; Trade Generics at Rs 30 Cr
- Plant-6 commissioning on track for H1 FY27 to boost capacity
- FY26 dividend Rs 13 Cr declared; Rs 47 Cr buyback completed without promoter participation
- EPS improved to Rs 8.46 in Q1FY27
- Focus on strategic partnerships, portfolio expansion, and operational excellence
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 WINDLAS — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add WINDLAS to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Windlas Biotech Limited
Important.
The summary above is generated automatically from Windlas Biotech Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.